General Publications November 30, 2015

“Inter Partes Review and the Pharmaceutical Industry: A New Normal,” New Jersey Law Journal, November 30, 2015.

Maegan Fuller writes that the role of inter partes review (IPR) proceedings will only increase in the intellectual property battles of the pharmaceutical industry. With the influx of IPRs come new issues and new questions not anticipated by the drafters of the Hatch-Waxman Act.
Meet the Author
Fuller, Maegan
Senior Associate
Phone: 212.210.9467
Media Contact
Nicholas Clarke
Senior Communications Manager
Phone: 212.210.1222

This website uses cookies to improve functionality and performance. For more information, see our Privacy Statement. Additional details for California consumers can be found here.